A prospective analysis of patients with advanced cancer revealed the effect delirium has on palliative care and symptom management at baseline and after 7 days of treatment.
Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.
In this randomized, double-blind, placebo-controlled study, researchers sought to determine the effect of including a checkpoint inhibitor in induction therapy for patients with extensive-stage small cell lung cancer.
Researchers sought to determine if nedaplatin could effectively manage malignancy-induced MPE in patients with cancer with less toxicity than cisplatin.
Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?September 14, 2018
[OncoTargets and Therapy] Although first-line therapy is effective, relapse is common; but many patients are good candidates for second-line therapy. This report reviews current published data on second-line therapies for advanced pancreatic cancer.
In a review of data from more than 20,000 veterans, researchers determined the effects of palliative care on suicide rates among veterans with advanced lung cancer.
Although corticosteroids are frequently used to manage adverse effects (AEs), data on AEs related to these agents are lacking. Therefore, these researchers sought to determine if better reporting of corticosteroid-related AEs would be of benefit.
Post-traumatic stress symptoms are linked to a greater symptom burden in hospitalized cancer patients.
In this retrospective study, researchers sought to determine the effectiveness of fentanyl for dyspnea in dying patients with advanced cancer.
A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.
A prospective study was conducted to determine the effectiveness of palliative sedation for patients with terminal illnesses who experience refractory symptoms.
Results of the phase 3 AXEPT study were used to determine the noninferiority of a modified XELIRI regimen vs a FOLFIRI regimen in terms of overall survival among patients with metastatic colorectal cancer (mCRC).
In this evaluation of palliative care use, investigators were able to determine how the focus of palliative care - coping, treatment, or advanced care planning - influenced patients' decisions on quality of life and decisions regarding chemotherapy and hospice care at the end of life.
Using MVIC and 6MWT, researchers sought to determine if patients' exercise behaviors changed after a diagnosis of advanced lung cancer.
Results of a nonblinded study demonstrate the value of incorporating early palliative care into oncologic care for patients with advanced cancer.
Researchers sought to determine the link between opioid use among patients with advanced cancer and health care use such as urgent care, inpatient, and emergency room visits.
Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
An analysis of select responses to a survey conducted by researchers from the College of Nursing at South Dakota State University identified oncology nurses' comfort level in handling end-of-life care and patient education.
Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.
Previous studies have shown that patients with advanced cancer may experience some financial relief integrating palliative care with standard oncologic care, but these results were coincidental findings and have not yet been fully explored.
WWW is not for the world-wide web, but it is an easy way to remember the 3 w's of communication with patients with advanced disease: wish, worry, wonder.
Investigators conducted a study involving more than 1000 patients with advanced cancer to assess the factors that contribute to prolonged hospital stays and increased risk for readmissions.
Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.
A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.
Lorazepam plus haloperidol is more effective than haloperidol alone at reducing agitation, study finds.
Sign Up for Free e-newsletters
- Cell Phones and Cancer Risk (Fact Sheet)
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- ASCO, SITC Release Recommendations for Clinical Trial Reporting of Immunotherapy Adverse Events
- CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
- New Method Estimates Risk for Breast Cancer Recurrence
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- The Efficacy and Safety of Apatinib for Refractory Malignancies: A Review and Meta-analysis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|